Citi raised the firm’s price target on Boston Scientific to $87 from $85 and keeps a Buy rating on the shares. The firm says the Q1 earnings season volatility creates opportunity in the medical technology space. The U.S. hospital capital purchasing environment is stable and China remains a point of volatility through anti-corruption policies and stimulus packages, the analyst tells investors in a research note. Citi left Boston Scientific (BSX) as a top pick while removing Irhythm Technologies (IRTC) and Intuitive Surgical (ISRG). The firm also added GE HealthCare (GEHC) as it recovers from a Q1 low and Insulet (PODD) as it expects a stronger second half of 2024 and momentum into 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $90 from $85 at Mizuho
- Boston Scientific Welcomes New Director and Updates Governance
- Catheter Precision appoints Marie-Claude Jacques as CCO
- Boston Scientific price target raised to $78 from $70 at Barclays
- Upcoming Deadline to Share in Boston Scientific Corporation (BSX) Class Action Settlement